gsk | Khurana And Khurana Advocates and IP Attorneys

GSK’s patent on lapatinib ditosylate revoked by IPAB

8th August, 2013 - 9:36 am Categories: IP Practice in India Pharma/Biotech Patent Litigations

GSK’s granted patent IN221171 (‘171) on lapatinib ditosylate (marketed as Tykerb), a tyrosine kinase inhibitor for treating breast cancer, was revoked by IPAB by its order of 27th July, 2013. A revocation application was filed by Fresenius Kabi Oncology Limited. The patent is revoked on ground of non-compliance with S.3d alone on basis of no … Continue reading GSK’s patent on lapatinib ditosylate revoked by IPAB

The Brand War!

3rd September, 2012 - 9:11 am Categories: Trademark Litigation

2 Comments

Brands are the biggest source of marketing. A company protects its brands by Trade Marks since they are often the main identity of their business or their key products. If the ownership of the Trade Mark is disputed, it can disrupt the business of both the concerned parties. A brand operation can undergo huge losses … Continue reading The Brand War!

Inventors, All Technologies Aren’t Worth Billions

31st July, 2011 - 6:23 pm Categories: Hi Tech Patent Commercialisation Patent Commercialisation Pharma- biotech- Patent Commercialisation

0 Comments

Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite of lot about Inventors mindset, specifically about their perspective of their own inventions. This article relates to our … Continue reading Inventors, All Technologies Aren’t Worth Billions

Tag: gsk

GSK’s patent on lapatinib ditosylate revoked by IPAB

The Brand War!

Inventors, All Technologies Aren’t Worth Billions

Categories

Archives